Literature DB >> 19622622

Asymptomatic children with multiple endocrine neoplasia type 1 mutations may harbor nonfunctioning pancreatic neuroendocrine tumors.

Paul J Newey1, Jeshmi Jeyabalan, Gerard V Walls, Paul T Christie, Fergus V Gleeson, Steve Gould, Paul R V Johnson, Rachel R Phillips, Fiona J Ryan, Brian Shine, Michael R Bowl, Rajesh V Thakker.   

Abstract

CONTEXT: Multiple endocrine neoplasia type 1 (MEN1) is characterized by the occurrence of parathyroid, pituitary, and pancreatic tumors. MEN1, an autosomal dominant disorder, has a high degree of penetrance, such that more than 95% of patients develop clinical manifestations by the fifth decade, although this is lower at approximately 50% by age 20 yr. However, the lower penetrance in the younger group, which is based on detecting hormone-secreting tumors, may be an underestimate because patients may have nonfunctioning tumors and be asymptomatic.
OBJECTIVE: The aim of the study was to evaluate the occurrence of nonfunctioning pancreatic neuroendocrine tumors in asymptomatic children with MEN1. PATIENTS: Twelve asymptomatic Northern European children, aged 6 to 16 yr, who were known to have MEN1 mutations were studied.
RESULTS: Two asymptomatic children, who were aged 12 and 14 yr, had normal plasma fasting gastrointestinal hormones and were found to have nonfunctioning pancreatic neuroendocrine tumors that were more than 2 cm in size. Surgery and immunostaining revealed that the tumors did not have significant expression of gastrointestinal hormones but did contain chromogranin A and synaptophysin, features consistent with those of nonfunctioning pancreatic neuroendocrine tumors. The tumors had a loss of menin expression. The 14 yr old also had primary hyperparathyroidism and a microprolactinoma, and the 12 yr old had a nonfunctioning pituitary microadenoma. Three other children had primary hyperparathyroidism and a microprolactinoma.
CONCLUSION: Nonfunctioning pancreatic neuroendocrine tumors may occur in asymptomatic children with MEN1 mutations, and screening for such enteropancreatic tumors in MEN1 children should be considered earlier than the age of 20 yr, as is currently recommended by the international guidelines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622622     DOI: 10.1210/jc.2009-0564

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

2.  MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors.

Authors:  Letizia Vannucci; Francesca Marini; Francesca Giusti; Simone Ciuffi; Francesco Tonelli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2017-05-22       Impact factor: 3.633

3.  Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?

Authors:  Jerena Manoharan; Friedhelm Raue; Caroline L Lopez; Max B Albers; Carmen Bollmann; Volker Fendrich; Emily P Slater; Detlef K Bartsch
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

4.  Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how.

Authors:  Alberto Falchetti
Journal:  F1000 Med Rep       Date:  2010-02-24

Review 5.  Multiple Endocrine Neoplasia: A Genetically Diverse Group of Familial Tumor Syndromes.

Authors:  M Cristina Pacheco
Journal:  J Pediatr Genet       Date:  2016-03-09

6.  Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients.

Authors:  Wei Qiu; Ioannis Christakis; Angelica Silva; Roland L Bassett; Liyun Cao; Qing H Meng; Elizabeth Gardner Grubbs; Hua Zhao; James C Yao; Jeffrey E Lee; Nancy D Perrier
Journal:  Clin Endocrinol (Oxf)       Date:  2016-06-30       Impact factor: 3.478

7.  Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2016-01-18

8.  Proliferation rates of multiple endocrine neoplasia type 1 (MEN1)-associated tumors.

Authors:  Gerard V Walls; Anita A C Reed; Jeshmi Jeyabalan; Mahsa Javid; Nathan R Hill; Brian Harding; Rajesh V Thakker
Journal:  Endocrinology       Date:  2012-09-28       Impact factor: 4.736

Review 9.  Current and emerging therapies for PNETs in patients with or without MEN1.

Authors:  Morten Frost; Kate E Lines; Rajesh V Thakker
Journal:  Nat Rev Endocrinol       Date:  2018-02-16       Impact factor: 43.330

10.  Multiple endocrine neoplasia type 1.

Authors:  R V Thakker
Journal:  Indian J Endocrinol Metab       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.